Literature DB >> 18225960

Genetic testing for warfarin dosing? Not yet ready for prime time.

Henry I Bussey, Ann K Wittkowsky, Elaine M Hylek, Marie B Walker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18225960     DOI： 10.1592/phco.28.2.141

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN： 0277-0008            Impact factor:   4.705


× No keyword cloud information.
  9 in total

1.  Debating clinical utility.

Authors:  Wylie Burke; A-M Laberge; N Press
Journal:  Public Health Genomics       Date:  2010-04-15       Impact factor: 2.000

2.  Integration of genetic, clinical, and INR data to refine warfarin dosing.

Authors:  P Lenzini; M Wadelius; S Kimmel; J L Anderson; A L Jorgensen; M Pirmohamed; M D Caldwell; N Limdi; J K Burmester; M B Dowd; P Angchaisuksiri; A R Bass; J Chen; N Eriksson; A Rane; J D Lindh; J F Carlquist; B D Horne; G Grice; P E Milligan; C Eby; J Shin; H Kim; D Kurnik; C M Stein; G McMillin; R C Pendleton; R L Berg; P Deloukas; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

3.  Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.

Authors:  Chun Li; Ute I Schwarz; Marylyn D Ritchie; Dan M Roden; C Michael Stein; Daniel Kurnik
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

4.  Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.

Authors:  Espen Molden; Cecilie Okkenhaug; Erik Ekker Solberg
Journal:  Eur J Clin Pharmacol       Date:  2010-03-31       Impact factor: 2.953

5.  Warfarin pharmacogenomics.

Authors:  Jiayi Li; Shan Wang; Joseph Barone; Brian Malone
Journal:  P T       Date:  2009-08

6.  Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.

Authors:  N S Ferder; C S Eby; E Deych; J K Harris; P M Ridker; P E Milligan; S Z Goldhaber; C R King; T Giri; H L McLeod; R J Glynn; B F Gage
Journal:  J Thromb Haemost       Date:  2009-10-30       Impact factor: 5.824

7.  Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.

Authors:  Andrea L Jorgensen; Sameh Al-Zubiedi; Jieying Eunice Zhang; Andrew Keniry; Anita Hanson; Dyfrig A Hughes; Diane van Eker; Lisa Stevens; Karen Hawkins; Cheng H Toh; Farhad Kamali; Ann K Daly; David Fitzmaurice; Alison Coffey; Paula R Williamson; Brian Kevin Park; Panos Deloukas; Munir Pirmohamed
Journal:  Pharmacogenet Genomics       Date:  2009-10       Impact factor: 2.089

8.  Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design.

Authors:  E J Do; P Lenzini; C S Eby; A R Bass; G A McMillin; S M Stevens; S C Woller; R C Pendleton; J L Anderson; P Proctor; R M Nunley; V Davila-Roman; B F Gage
Journal:  Pharmacogenomics J       Date:  2011-05-24       Impact factor: 3.550

9.  Estimation of the warfarin dose with clinical and pharmacogenetic data.

Authors:  T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.